Other Medicines
Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 13-24 out of 34 results
Other Medicines
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1
Cardiometabolic Disease
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Neurology
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease
Neurology
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial
Neurology
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
Cardiometabolic Disease
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
Neurology
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
Neurology
ION582 Data Presented at the 2025 FAST Conference
Neurology
Zilganersen Data Presented at the Child Neurology Society's 54th Annual Meeting
Neurology
Ulefnersen Data Presented at the Northeast ALS Consortium Annual Meeting
Other Medicines
Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis